Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 15/20 | 0.50 |
| ▸ | EPHA2 | P29317 | 15/20 | 0.50 |
| ▸ | FLT1 | P17948 | 14/20 | 0.50 |
| ▸ | ERBB2 | P04626 | 12/20 | 0.50 |
| ▸ | EPHB4 | P54760 | 10/20 | 0.50 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 3/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | KIF5B | P33176 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695042 | 1.00 | KDR (0.50) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695030 | 1.00 | KDR (0.50) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695027 | 0.96 | EPHA2 (0.47) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695015 | 0.96 | EPHA2 (0.47) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695039 | 0.96 | EPHA2 (0.47) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695048 | 0.89 | ERBB2 (0.62) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695019 | 0.89 | ERBB2 (0.62) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695050 | 0.89 | ERBB2 (0.62) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695049 | 0.89 | EGFR (0.52) | KDREPHA2FLT1ERBB2EPHB4 | |
| SCHEMBL20695008 | 0.88 | KDR (0.57) | KDREPHA2FLT1ERBB2EPHB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2021-11-09 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG (SHANGHAI) BIO-PHARMACEUTICAL CO., LTD. (CN) | 2020-10-01 | — | — | US | disclosed |
| EP-3438107-B1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | WEISHANG SHANGHAI BIO PHARMACEUTICAL CO LTD (CN) | 2020-06-10 | — | — | EP | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438107-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | Weishang (Shanghai) Bio-Pharmaceutical Co., Ltd. (CN) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308140-A1 | SUBSTITUTED QUINAZOLINE COMPOUND HAVING BLOOD-BRAIN BARRIER PENETRATION CAPABILITY | KDR, FLT4, EGFR | KDR 1/4885EPHA2 496/4885FLT1 7/4885 |
| US-11168067-B2 | Substituted quinazoline compound having blood-brain barrier penetration capability | KDR, FLT4, EGFR | KDR 1/4885EPHA2 496/4885FLT1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.